






















# Reference Data

---

# Business segments and major products

Segment	Description	Major products					
<b>Imaging Products Business</b>	Digital camera-interchangeable lens type Interchangeable lens Digital cinema camera	 Digital Cinema Camera [ZR]	 Mirrorless Camera [Zf Silver]	 [NIKKOR Z 70-200mm f/2.8 VR S II]	 [V-RAPTOR [XE] Z Mount]		
<b>Precision Equipment Business</b>	FPD lithography system Semiconductor lithography system Digital lithography system Alignment station	 FPD Lithography System [FX-88SL]	 ArF Immersion Scanner [NSR-S636E]	 Digital Lithography System [DSP-100]	 Alignment Station [Litho Booster]		
<b>Healthcare Business</b>	Biological microscope (Life Science Solutions) Retinal diagnostic imaging system (Eye Care Solutions) Contract Cell Development and Manufacturing	 Confocal Microscope System [AX/AX R]	 Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT [Silverstone]	 Contract Cell Development and Manufacturing			
<b>Industry Business (formerly Components Business)</b>	EUV related components Optical parts, Optical components Encoders, Measuring and inspection systems Photomask substrates for FPD	 Optical Components	 Multi-turn External Battery-Free Absolute Encoder [MAR-M700MFA]	 Video Meas. System [NEXIV VM Series]	 Laser Radar [APDIS MV5X]	 Versatile Large-Envelope X-ray and CT System [VOXLS 40 C 450]	 Photomask Substrates for FPD
<b>Digital Manufacturing Business</b>	Metal 3D printer Optical processing machine 3D scanner Contract material processing	 Metal 3D Printer [NXG 600E]	 Material Processing Machine [Lasermeister LM300A]	 3D Scanner [Lasermeister SB100]	 Contract Material Processing		

# The year ended March 31, 2026: Financial Highlights

Billions of Yen	FY2023/3	FY2024/3	FY2025/3			FY2026/3		
	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
<b>Revenue</b>	628.1	717.2	332.7	382.5	715.2	<b>312.9</b>	<b>364.2</b>	<b>677.1</b>
<b>Operating profit</b>	54.9	39.7	5.8	-3.4	2.4	<b>-4.8</b>	<b>-107.6</b>	<b>-112.4</b>
% vs Revenue	8.7%	5.5%	1.7%	-0.9%	0.3%	-1.5%	-29.5%	-16.6%
<b>Profit before tax</b>	57.0	42.6	4.4	0.1	4.5	<b>-5.2</b>	<b>-101.3</b>	<b>-106.5</b>
% vs Revenue	9.1%	5.9%	1.3%	0.0%	0.6%	-1.7%	-27.8%	-15.7%
<b>Profit attributable to owners of parent</b>	44.9	32.5	2.9	3.2	6.1	<b>5.3</b>	<b>-91.3</b>	<b>-86.0</b>
% vs Revenue	7.2%	4.5%	0.9%	0.8%	0.9%	1.7%	-25.1%	-12.7%
<b>FCF</b>	-112.1	-10.6		-21.7			<b>-170.0</b>	
<b>ROE</b>	7.4%	5.0%		0.9%			<b>-14.1%</b>	
<b>EPS</b>	¥125.46	¥94.03		¥17.86			<b>-¥261.57</b>	
<b>Annual Dividends</b>	¥45	¥50		¥50			<b>¥40</b>	
Exchange Rate: US\$	¥135	¥145	¥153	¥152	¥153	<b>¥146</b>	<b>¥156</b>	<b>¥151</b>
EURO	¥141	¥157	¥166	¥162	¥164	<b>¥168</b>	<b>¥182</b>	<b>¥175</b>

# The year ended March 31, 2026: Performance by Segment

Billions of Yen		FY2025/3 Actual (A)			FY2026/3 Actual (B)			Change (B)-(A)		
		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
<b>Imaging Products Business</b>	Revenue	151.7	143.6	295.3	<b>145.0</b>	<b>145.0</b>	<b>290.0</b>	-6.7	+1.4	-5.3
	Operating profit	28.8	12.5	41.3	<b>15.1</b>	<b>1.6</b>	<b>16.7</b>	-13.7	-10.9	-24.6
<b>Precision Equipment Business</b>	Revenue	81.5	120.4	201.9	<b>69.8</b>	<b>97.4</b>	<b>167.2</b>	-11.7	-23.0	-34.7
	Operating profit	0.9	0.6	1.5	<b>3.0</b>	<b>-7.5</b>	<b>-4.5</b>	+2.1	-8.1	-6.0
<b>Healthcare Business</b>	Revenue	55.1	61.3	116.4	<b>51.2</b>	<b>60.7</b>	<b>111.9</b>	-3.9	-0.6	-4.5
	Operating profit	1.3	5.4	6.7	<b>0.3</b>	<b>1.2</b>	<b>1.5</b>	-1.0	-4.2	-5.2
<b>Components Business</b>	Revenue	30.4	43.7	74.1	<b>35.1</b>	<b>41.0</b>	<b>76.1</b>	+4.7	-2.7	+2.0
	Operating profit	1.4	5.7	7.1	<b>5.2</b>	<b>4.3</b>	<b>9.5</b>	+3.8	-1.4	+2.4
<b>Digital Manufacturing Business</b>	Revenue	11.7	11.6	23.3	<b>9.8</b>	<b>18.2</b>	<b>28.0</b>	-1.9	+6.6	+4.7
	Operating profit	-6.4	-8.8	-15.2	<b>-8.9</b>	<b>-97.3</b>	<b>-106.2</b>	-2.5	-88.5	-91.0
<b>Others</b>	Revenue	2.0	2.0	4.0	<b>1.8</b>	<b>1.8</b>	<b>3.6</b>	-0.2	-0.2	-0.4
	Operating profit	0.6	2.3	2.9	<b>-0.5</b>	<b>1.9</b>	<b>1.4</b>	-1.1	-0.4	-1.5
<b>Corporate expenses, etc.</b>	Operating profit	-20.9	-21.1	-42.0	<b>-19.0</b>	<b>-11.8</b>	<b>-30.8</b>	+1.9	+9.3	+11.2
	Broken out: Expense related to investment in growth	-9.9	-10.5	-20.4	<b>-8.4</b>	<b>-9.4</b>	<b>-17.8</b>	+1.5	+1.1	+2.6
	Broken out: Expense for administration department	-12.0	-11.5	-23.5	<b>-8.9</b>	<b>-4.3</b>	<b>-13.2</b>	+3.1	+7.2	+10.3
	Broken out: Elimination of intersegment transactions	1.0	0.9	1.9	<b>-1.7</b>	<b>1.9</b>	<b>0.2</b>	-2.7	+1.0	-1.7
<b>Consolidated</b>	Revenue	332.7	382.5	715.2	<b>312.9</b>	<b>364.2</b>	<b>677.1</b>	-19.8	-18.3	-38.1
	Operating profit	5.8	-3.4	2.4	<b>-4.8</b>	<b>-107.6</b>	<b>-112.4</b>	-10.6	-104.2	-114.8

# The year ended March 31, 2026: Performance by Segment

Billions of Yen		FY2025/3	Previous Forecast	FY2026/3	Change		Change	
		Actual (A)	(Feb. 6) (B)	Actual (C)	Amount (C)-(A)	% (C)/(A)	Amount (C)-(B)	% (C)/(B)
Imaging Products Business	Revenue	295.3	290.0	<b>290.0</b>	-5.3	-1.8%	± 0.0	+0.0%
	Operating profit	41.3 (43.2)	21.0	<b>16.7</b> <b>(19.9)</b>	-24.6	-59.5%	-4.3	-20.4%
Precision Equipment Business	Revenue	201.9	165.0	<b>167.2</b>	-34.7	-17.2%	+2.2	+1.4%
	Operating profit	1.5 (15.6)	1.0 (2.9)	<b>-4.5</b> <b>(4.7)</b>	-6.0	-	-5.5	-
Healthcare Business	Revenue	116.4	112.0	<b>111.9</b>	-4.5	-3.9%	-0.1	-0.1%
	Operating profit	6.7 (8.7)	2.5 (5.9)	<b>1.5</b> <b>(4.4)</b>	-5.2	-76.8%	-1.0	-37.6%
Components Business	Revenue	74.1	79.0	<b>76.1</b>	+2.0	+2.8%	-2.9	-3.6%
	Operating profit	7.1 (8.9)	10.0 -	<b>9.5</b> <b>(11.5)</b>	+2.4	+33.0%	-0.5	-4.5%
Digital Manufacturing Business	Revenue	23.3	25.0	<b>28.0</b>	+4.7	+20.3%	+3.0	+12.4%
	Operating profit	-15.2 -	-105.0 (-13.8)	<b>-106.2</b> <b>(-14.9)</b>	-91.0	-	-1.2	-
Others (incl. Corporate expenses, etc.)	Revenue	4.0	4.0	<b>3.6</b>	-0.4	-8.7%	-0.4	-8.4%
	Operating profit	-39.1 (-32.0)	-29.5 (-33.3)	<b>-29.4</b> <b>(-32.4)</b>	+9.7	-	+0.1	-
Consolidated	Revenue	715.2	675.0	<b>677.1</b>	-38.1	-5.3%	+2.1	+0.3%
	Operating profit	2.4 (29.6)	-100.0 (-7.5)	<b>-112.4</b> <b>(-6.8)</b>	-114.8	-	-12.4	-

Note: Figures in parentheses for operating profit exclude one-time profit and losses.

# The year ended March 31, 2026: Quarterly Performance by Segment

Billions of Yen		FY2026/3				
		Q1	Q2	Q3	Q4	Full Year
<b>Imaging Products Business</b>	Revenue	80.0	65.0	84.0	61.0	290.0
	Operating profit	11.0	4.1	5.8	-4.2	16.7
<b>Precision Equipment Business</b>	Revenue	33.8	36.0	34.8	62.6	167.2
	Operating profit	1.8	1.2	-2.4	-5.1	-4.5
<b>Healthcare Business</b>	Revenue	23.1	28.1	27.8	32.9	111.9
	Operating profit	-1.8	2.1	-0.9	2.1	1.5
<b>Components Business</b>	Revenue	15.1	20.0	16.7	24.3	76.1
	Operating profit	1.8	3.4	1.4	2.9	9.5
<b>Digital Manufacturing Business</b>	Revenue	5.0	4.8	6.8	11.4	28.0
	Operating profit	-4.1	-4.8	-94.5	-2.8	-106.2
<b>Others</b>	Revenue	0.8	1.0	0.9	0.9	3.6
	Operating profit	-0.2	-0.3	-1.0	2.9	1.4
<b>Corporate expenses, etc.</b>	Operating profit	-9.6	-9.4	-7.1	-4.7	-30.8
		(-9.0)	(-8.9)	(-7.0)	(-9.0)	(-33.8)
	Broken out: Expense related to investment in growth	-4.1	-4.3	-4.2	-5.2	-17.8
	Broken out: Expense for administration department	-4.0	-4.9	-4.1	-0.2	-13.2
<b>Consolidated</b>	Revenue	158.1	154.8	171.0	193.2	677.1
	Operating profit	-1.1	-3.7	-98.8	-8.8	-112.4
		(±0.0)	(-4.8)	(-6.3)	(4.2)	(-6.8)

Note: Figures in parentheses for operating profit exclude one-time profit and losses.

# The year ended March 31, 2025: One-Time Costs by Segment

Billions of Yen	FY2025/3					Details
	Q1	Q2	Q3	Q4	Full Year	
<b>Imaging Products Business</b>	-0.5	-	-	-1.4	-1.9	Q1: RED acquisition related expenses -0.5 Q4: MRMC* fixed asset impairment losses -0.8, intellectual property related expenses -0.6
<b>Precision Equipment Business</b>	-	-	-	-14.1	-14.1	Impairment of fixed assets -7.8, inventory write-downs -5.0, restructuring costs (optimization of service bases) -1.2
<b>Healthcare Business</b>	-0.5	-0.4	-0.4	-0.7	-2.0	Eye Care Solutions investigation costs, etc.
<b>Components Business</b>	-	-	-0.8	-1.0	-1.8	Restructuring costs (optimization of organization of the formerly Industrial Metrology Business) -1.8
<b>Digital Manufacturing Business</b>	-	-	-	-	-	
<b>Others</b> (incl. Corporate expenses, etc.)	-	-5.1	-1.3	-0.7	-7.1	Q2: HQ relocation costs -5.1 Q3/Q4: restructuring costs (footprint reorganization) -1.8 etc.
<b>Consolidated</b>	-1.0	-5.5	-2.6	-18.1	-27.2	

# The year ended March 31, 2026: One-Time Profit/Losses by Segment

Billions of Yen	FY2025/3					Details
	Q1	Q2	Q3	Q4	Full Year	
<b>Imaging Products Business</b>	-	-	-	-3.2	-3.2	Costs related to the sale of MRMC shares -3.2
<b>Precision Equipment Business</b>	-	+2.1	-	-11.3	-9.2	Q2: Gain from transfer of business +2.9 and restructuring costs (optimization of service bases) -0.8 Q4: fixed-asset impairment losses -5.7, inventory write-downs -5.5
<b>Healthcare Business</b>	-0.5	-0.4	-1.8	-0.1	-2.9	Q1-Q4: Eye Care Solutions investigation costs, etc. -1.4 Q3: Eye Care Solutions provision -1.4
<b>Components Business</b>	-	-	-	-2.0	-2.0	Avonix* fixed assets impairment losses -1.4, restructuring costs -0.6
<b>Digital Manufacturing Business</b>	-	-	-90.6	-0.6	-91.3	Q3: Impairment losses on fixed assets -90.6 Q4: Restructuring costs -0.6
<b>Others</b> (incl. Corporate expenses, etc.)	-0.6	-0.5	-0.1	+4.3	+3.0	Q1-Q3: Expenses related to footprint reorganization -1.2 Q4: NCC** fixed-asset impairment losses -0.6, Capital gain on sale of idle land +4.9
<b>Consolidated</b>	-1.1	+1.1	-92.5	-13.0	-105.6	

\* Avonix Imaging, Inc. was acquired in 2023 and is mainly in the business of the development and manufacture of X-ray and CT systems

\*\* Nikon Creates (NCC) is mainly in the business of the planning, filming and production of next-generation imaging contents

# Forecast for the year ending March 31, 2027: Financial Highlights

Billions of Yen	FY2026/3 Actual (A)			FY2027/3 Forecast (B)			Change (B)-(A)		
	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
<b>Revenue</b>	312.9	364.2	677.1	<b>343.0</b>	<b>397.0</b>	<b>740.0</b>	+30.1	+32.8	+62.9
<b>Operating profit</b>	-4.8	-107.6	-112.4	<b>-7.0</b>	<b>17.0</b>	<b>10.0</b>	-2.2	+124.6	+122.4
% vs Revenue	-1.5%	-29.5%	-16.6%	<b>-2.0%</b>	<b>4.3%</b>	<b>1.4%</b>	-0.5P	+33.8P	+18.0P
<b>Profit before tax</b>	-5.2	-101.3	-106.5	<b>-5.0</b>	<b>19.0</b>	<b>14.0</b>	+0.2	+120.3	+120.5
% vs Revenue	-1.7%	-27.8%	-15.7%	<b>-1.5%</b>	<b>4.8%</b>	<b>1.9%</b>	+0.2P	+32.6P	+17.6P
<b>Profit attributable to owners of parent</b>	5.3	-91.3	-86.0	<b>-3.0</b>	<b>13.0</b>	<b>10.0</b>	-8.3	+104.3	+96.0
% vs Revenue	1.7%	-25.1%	-12.7%	<b>-0.9%</b>	<b>3.3%</b>	<b>1.4%</b>	-2.6P	+28.4P	+14.1P
<b>ROE</b>	-14.1%			<b>1.7%</b>			+15.8P		
<b>EPS</b>	-¥261.57			<b>¥30.36</b>			¥291.93		
<b>Annual Dividends</b>	¥40			<b>¥20</b>			-¥20		
Exchange Rate: US\$	¥146	¥156	¥151	<b>¥155</b>	<b>¥155</b>	<b>¥155</b>	+¥9	-¥1	+¥4
EURO	¥168	¥182	¥175	<b>¥180</b>	<b>¥180</b>	<b>¥180</b>	+¥12	-¥2	+¥5

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 329.4M shares


# Forecast for the year ending March 31, 2027: Forecast by Segment

Billions of Yen		FY2026/3 Actual (A)			FY2027/3 Forecast (B)			Change (B)-(A)		
		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue	145.0	145.1	290.1	<b>143.0</b>	<b>160.0</b>	<b>303.0</b>	-2.0	+14.9	+12.9
	Operating profit	15.4	1.8	17.2	<b>7.5</b>	<b>8.5</b>	<b>16.0</b>	-7.9	+6.7	-1.2
Precision Equipment Business	Revenue	69.8	97.4	167.2	<b>89.0</b>	<b>99.0</b>	<b>188.0</b>	+19.2	+1.6	+20.8
	Operating profit	3.0	-7.5	-4.5	<b>2.5</b>	<b>9.5</b>	<b>12.0</b>	-0.5	+17.0	+16.5
Healthcare Business	Revenue	51.2	60.7	111.9	<b>58.0</b>	<b>69.0</b>	<b>127.0</b>	+6.8	+8.3	+15.1
	Operating profit	0.3	1.2	1.5	<b>0.0</b>	<b>6.0</b>	<b>6.0</b>	-0.3	+4.8	+4.5
Industry Business (formerly Components Business)	Revenue	35.0	41.1	76.1	<b>34.0</b>	<b>50.0</b>	<b>84.0</b>	-1.0	+8.9	+7.9
	Operating profit	4.9	4.1	9.0	<b>2.5</b>	<b>9.5</b>	<b>12.0</b>	-2.4	+5.4	+3.0
Digital Manufacturing Business	Revenue	9.8	18.2	28.0	<b>17.0</b>	<b>17.0</b>	<b>34.0</b>	+7.2	-1.2	+6.0
	Operating profit	-8.9	-97.3	-106.2	<b>-2.5</b>	<b>-1.5</b>	<b>-4.0</b>	+6.4	+95.8	+102.2
Others	Revenue	1.8	1.8	3.6	<b>2.0</b>	<b>2.0</b>	<b>4.0</b>	+0.2	+0.2	+0.4
	Operating profit	-0.5	1.9	1.4	<b>-1.0</b>	<b>3.0</b>	<b>2.0</b>	-0.5	+1.1	+0.6
Corporate expenses, etc.	Operating profit	-19.0	-11.7	-30.7	<b>-16.0</b>	<b>-18.0</b>	<b>-34.0</b>	+3.0	-6.3	-3.3
	Broken out: Expense related to investment in growth	-8.4	-9.4	-17.8	<b>-7.5</b>	<b>-8.0</b>	<b>-15.5</b>	+0.9	+1.4	+2.3
	Broken out: Expense for administration department	-8.9	-4.3	-13.2	<b>-8.5</b>	<b>-8.5</b>	<b>-17.0</b>	+0.4	-4.2	-3.8
	Broken out: Elimination of intersegment transactions	-1.7	2.0	0.3	<b>0.0</b>	<b>-1.5</b>	<b>-1.5</b>	+1.7	-3.5	-1.8
<b>Consolidated</b>	Revenue	312.9	364.2	677.1	<b>343.0</b>	<b>397.0</b>	<b>740.0</b>	+30.1	+32.8	+62.9
	Operating profit	-4.8	-107.6	-112.4	<b>-7.0</b>	<b>17.0</b>	<b>10.0</b>	-2.2	+124.6	+122.4


Note: FY2026/3 results have been re-stated to reflect segmentation changes.

# The year ended March 31, 2026: Financial Position

## ASSET




## LIABILITIES/EQUITY




Note: Cash and cash equivalents exclude time deposits with maturities of three months or more.  
Equity ratio is the ratio of equity attributable to owners of parent to total assets.

# Capital Expenditures, Depreciation & Amortization, and Inventories

### CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION



### BREAKDOWN OF INVENTORIES




Note: Capital expenditures include right-of-use assets.  
 Depreciation & amortization include right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination.

# The year ended March 31, 2026: Revenue Breakdown


## BY SEGMENT

Billions of Yen



## BY REGION


Billions of Yen




Note: The outside and inside circles show the breakdown of FY2026/3 revenue of ¥677.1B and FY2025/3 revenue of ¥715.2B, respectively.

# Forecast for the year ending March 31, 2027: R&D Expenditures

### R&D EXPENDITURES




### R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures include capitalization of some development expenditures.  
 Note: FY2026/3 results have been re-stated to reflect segmentation changes.


# Cash Flow History



Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents


# Imaging Products Business: Sales Units

**SALES IN UNITS BY PRODUCT CATEGORY**




# Forecast for the year ending March 31, 2027: Precision Equipment Business Sales Units

### FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION




### SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System."  
The unit sales of new semiconductor lithography systems are 27 units in FY2023/3, 31 units in FY2024/3, 18 units in FY2025/3, 22 units in FY2026/3, and 23 units (forecast) in FY2027/3.


# Precision Equipment Business: Sales Units

## FPD LITHOGRAPHY SYSTEMS SALES IN UNITS BY GENERATION



# Precision Equipment Business: Sales Units

**SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES  
IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)**



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System."

# Forecast for the year ending March 31, 2027: Foreign Exchange Impact

	Exchange Rate	Financial Impact from Fluctuation by 1 yen	
	FY2027/3 Forecast	Revenue	Operating Profit
US \$	¥155	Approx. ¥2.3B	Approx. ¥0.5B
EURO	¥180	Approx. ¥0.7B	Approx. ¥0.3B

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and EURO.

## Disclaimer Regarding Forecast and Projections

---

Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

